Portico hits noninferiority, but safety looks doubtful. Abbott might want to prioritise a different approach.
Feasibility trial success could mean a new therapy, but not for a few years yet.
Intuitive Surgical makes the most money per employee – but the title of “most improved” goes to Philips.
First-look data on Abbott’s tricuspid-focused MitraClip follow-on device are promising, but can TriClip emulate its predecessor’s success?
A tiny Israeli company has beaten some of the biggest medtechs in the world to the wireless charging of heart pumps.
Transcatheter mitral valve replacement is wrenching the spotlight away from the repair devices that grabbed the headlines last summer.
Despite encouraging interim pivotal data, Carmat’s artificial heart seems as far from market as ever.
The immensely complex and long-running intertwined litigation between the two medtechs has been brought to an end.
Amid a huge furore over unsafe implanted medical devices the US FDA has released new proposals that are cautious to the point of toothlessness – and wouldn’t affect most…